145 related articles for article (PubMed ID: 18680444)
1. Insulin glargine and its role in glycaemic management of Type 2 diabetes.
Elrishi MA; Jarvis J; Khunti K; Davies MJ
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1099-110. PubMed ID: 18680444
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
3. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
4. Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes.
Rosenstock J; Owens D
Expert Opin Pharmacother; 2004 Jan; 5(1):1-2; author reply 2-3. PubMed ID: 14680430
[No Abstract] [Full Text] [Related]
5. Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience.
Schreiber SA
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():24-34. PubMed ID: 18577154
[TBL] [Abstract][Full Text] [Related]
6. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
7. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
Spirk D; Lareida J; Scheidegger K; Diem P
Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
[TBL] [Abstract][Full Text] [Related]
8. Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.
Mathieu C; Robbrecht S
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():14-23. PubMed ID: 18577153
[TBL] [Abstract][Full Text] [Related]
9. Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100.
Hollander PA; Kiljanski J; Spaepen E; Harris CJ
Diabetes Obes Metab; 2019 Nov; 21(11):2413-2421. PubMed ID: 31264764
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
12. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
[No Abstract] [Full Text] [Related]
13. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
14. Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?
Fenske WK; Pournaras DJ; Aasheim ET; Miras AD; Scopinaro N; Scholtz S; le Roux CW
Obes Surg; 2012 Jan; 22(1):90-6. PubMed ID: 22052198
[TBL] [Abstract][Full Text] [Related]
15. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
Chatterjee S; Tringham JR; Davies MJ
Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721
[TBL] [Abstract][Full Text] [Related]
17. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
18. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
Chatterjee S; Khunti K; Davies MJ
Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products.
Bullano MF; Fisher MD; Grochulski WD; Menditto L; Willey VJ
Am J Health Syst Pharm; 2006 Dec; 63(24):2473-82. PubMed ID: 17158695
[TBL] [Abstract][Full Text] [Related]
20. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
